A carregar...
Safety, tolerability and pharmacodynamics of a novel immunomodulator, MIS416, in patients with chronic progressive multiple sclerosis
BACKGROUND: Preclinical studies have demonstrated that MIS416, a bacterially derived immune modulator, targets myeloid cells following systemic delivery. MIS416 stimulated myeloid cells have the capacity to regulate innate inflammation, a potential therapeutic target for progressive multiple scleros...
Na minha lista:
| Publicado no: | Mult Scler J Exp Transl Clin |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5433401/ https://ncbi.nlm.nih.gov/pubmed/28607691 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2055217315583385 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|